Sunshine Biopharma closes $6.0 million public offering at $0.55 per unit
Sunshine Biopharma (SBFM) closed a best-efforts public offering on October 9, 2026, with gross proceeds of approximately $6.0 million before placement agent fees and other expenses. The offering included Series D warrants with a $0.66 exercise price, which the company says could bring up to about $14.4 million more if fully exercised, though no assurance is given that any warrants will be exercised.
Key points
- Common units sold at $0.55 each, with each unit including one share of common stock and two Series D warrants exercisable at $0.66 per share over five years.
- Placement agent Aegis Capital Corp. received a 7% fee on the public offering price plus a 1% non-accountable expense allowance.
- The company expects to use net proceeds for general corporate purposes and working capital.
- The offering was made under a Form S-1 (File No. 333-299274) declared effective on October 7, 2026.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 09, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.